Clinical trials: Diffuse Parenchymal Lung Diseases
Idiopathic Pulmonary Fibrosis
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis.
- Trial name
- AURORA (NCT06736990)
- Testing
- CAL101
- Where
- 54 sites in United States, Denmark and 9 more
- Volunteers
- 150 people
- Sponsor
- Calluna Pharma AS
Interstitial Lung Disease (ILD)
Confocal Laser Endomicroscopy Guided Cryobiopsy in the Diagnosis of Interstitial Lung Disease
This prospective, single-center, randomized controlled trial compares pCLE-guided TBLC with conventional TBLC in patients with suspected interstitial lung disease.
- Trial name
- NCT06741826
- Testing
- pCLE-guided transbronchial lung cryobiopsy, Fluoroscopy-guided transbronchial lung cryobiopsy
- Where
- China
- Volunteers
- 430 people
- Sponsor
- China-Japan Friendship Hospital
Idiopathic Pulmonary Fibrosis
Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients
This study has two objectives: 1. To assess the association between nintedanib adherence trajectory group (as measured from a Group-based Trajectory Modelling (GBTM)) and health care resource use, with a focus on inpatient…
- Trial name
- NCT05870956
- Testing
- Nintedanib
- Where
- United States
- Volunteers
- 1,798 people
- Sponsor
- Boehringer Ingelheim
Interstitial Lung Diseases
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are…
- Trial name
- NCT07540988
- Testing
- Nerandomilast
- Where
- 162 sites in United States, Argentina and 18 more
- Volunteers
- 466 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis (IPF)
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
The purpose of this revised Phase IIa study is to demonstrate safety of INS018_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT05975983
- Testing
- INS018_055
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
The study consists of 2 parts: Part A is a randomized, multiple-dose, double-blind, placebo-controlled sequential dose escalation study to evaluate GS-6624 in subjects with Idiopathic Pulmonary Fibrosis (IPF) and was completed in…
- Trial name
- NCT01362231
- Testing
- GS-6624
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
Granulomatosis With Polyangiitis, Wegener Granulomatosis
The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
This is a randomized controlled trial in patients with a diagnosis of granulomatosis with polyangiitis (GPA; Wegener's)that are in remission to evaluate the effects of using low-dose glucocorticoids ( 5 mg/day of prednisone) as…
- Conditions
- Granulomatosis With Polyangiitis, Wegener Granulomatosis, Vasculitis
- Trial name
- TAPIR (NCT01933724)
- Testing
- 5 mg prednisone, 0 mg prednisone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of South Florida
Chronic Kidney Disease
Furosemide Stress Test as a Predictor of Tubular Function in Chronic Kidney Disease
In kidney diseases, tubule-interstitium has become much more relevant, as formerly only the glomerulus was considered to have the main importance.
- Trial name
- FST-IFTA (NCT02417883)
- Testing
- Furosemide
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
ANCA Associated Vasculitis, Microscopic Polyangiitis
Hydroxychloroquine in ANCA Vasculitis Evaluation
The purpose of this study is to find out whether hydroxychloroquine, in addition to background treatments, reduces disease activity in patients with Anti-Neutrophilic Cytoplasmic Autoantibodies (ANCA) Vasculitis, a group of…
- Conditions
- ANCA Associated Vasculitis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Wegener Granulomatosis
- Trial name
- HAVEN (NCT04316494)
- Testing
- Hydroxychloroquine
- Where
- 18 sites in United Kingdom
- Volunteers
- 43 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Idiopathic Pulmonary Fibrosis, Pulmonary Disease
Influence of Socioeconomic and Environmental Factors on the Natural History of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis(IPF) is the most common idiopathic interstitial lung disease whose cause is unknown. With age and gender, socio-economic factors are the most influential indicators of health.
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Disease, Pulmonary Medicine
- Trial name
- EXPOSOMFPI (NCT04619199)
- Testing
- Blood sample
- Where
- 16 sites in France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Interstitial Lung Disease
Ambulatory Oxygen for ILD
People with interstitial lung disease (ILD) are frequently prescribed ambulatory oxygen, to increase oxygen levels in the blood during daily activities. The best way of delivering this type of oxygen has not been established.
- Trial name
- NCT01906931
- Testing
- Portable oxygen concentrator, Portable oxygen cylinder
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Anne Holland
Idiopathic Pulmonary Fibrosis, Obstructive Sleep Apnea
Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF
This study will evaluate the effect of CPAP therapy on esophageal pH and lung inflammation in patients with idiopathic pulmonary fibrosis (IPF) and sleep apnea.
- Conditions
- Idiopathic Pulmonary Fibrosis, Obstructive Sleep Apnea, Gastro Esophageal Reflux
- Trial name
- NCT05359965
- Testing
- Positive Airway Pressure
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Arizona
Idiopathic Pulmonary Fibrosis
Inspiratory Effort and Respiratory Mechanics in Spontaneously Breathing Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Matched Control Study
Idiopathic pulmonary fibrosis is a life-threatening lung disease characterized by progressive deterioration of lung function and a median survival time of 3-5 years from diagnosis.
- Trial name
- IERATIC (NCT05313672)
- Volunteers
- 20 people
- Sponsor
- Roberto Tonelli
Idiopathic Pulmonary Fibrosis
Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions
A Randomized, Open-Label, Two-Period, Double-Crossover Comparative Study on the Pharmacokinetics of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Chinese Subjects under Fed Conditions Primary objective…
- Trial name
- NCT06589921
- Testing
- Pirfenidone Modified-Release Tablets, Pirfenidone Tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.
Chronic Obstructive Pulmonary Disease, Asthma
Hyperoxia During Pulmonary Rehabilitation in Chronic Lung Disease - Does it Matter?
Chronic respiratory diseases are a global burden. Treatment options have improved in recent years, pulmonary rehabilitation plays a key role.
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Pulmonary Hypertension, Interstitial Lung Disease
- Trial name
- NCT06174207
- Testing
- Oxygen
- Where
- Switzerland
- Volunteers
- 23 people
- Sponsor
- Eastern Switzerland University of Applied Sciences
Idiopathic Pulmonary Fibrosis (IPF)
Inhaled NAC in Treatment of IPF
This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis.
- Trial name
- NCT03720483
- Where
- United States
- Sponsor
- University of Colorado, Denver
Noninvasive Ventilation, Lung Diseases, Interstitial
Non-invasive Ventilation in Patients With Interstitial Lung Disease - a Feasibility Study
The efficiency of non-invasive ventilation (NIV) in hypercapnic patients with chronic obstructive pulmonary disease during pulmonary rehabilitation has been shown in numerous studies.
- Trial name
- NCT02377739
- Testing
- non-invasive ventilation
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Schön Klinik Berchtesgadener Land
Idiopathic Pulmonary Fibrosis (IPF)
A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
This study is a multicentre, randomised, double-blind, placebo-controlled, adaptive design clinical trial to evaluate the efficacy and safety of TDI01 suspension in the treatment of idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT07464912
- Testing
- TDI01
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis
A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015
This is a Phase 1A, first in human, randomized, double-blinded, placebo-controlled, dose escalation study of PMG1015 in healthy adult volunteers.
- Trial name
- NCT05022771
- Testing
- PMG1015 Dose 1, PMG1015 Dose 2, PMG1015 Dose 3
- Where
- Australia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Pulmongene Ltd.
Idiopathic Pulmonary Fibrosis
Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
Primary Objective: To evaluate, in comparison with placebo, the efficacy of 2 dose levels/regimens of SAR156597 administered subcutaneously during 52 weeks on lung function of participants with Idiopathic Pulmonary Fibrosis…
- Trial name
- ESTAIR (NCT02345070)
- Testing
- SAR156597
- Where
- 101 sites in United States, Argentina and 17 more
- Volunteers
- 327 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.